Trial Profile

A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pridopidine (Primary)
Indications Huntington's disease
Focus Adverse reactions
Acronyms Open PRIDE-HD
Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

17 Aug 2018 Status changed to discontinued as this study served its purpose in providing considerable safety data. The decision to terminate the studies was not based on any new or emerging safety concern.
12 Dec 2017 Planned End Date changed from 27 Apr 2023 to 31 Jan 2018.
12 Dec 2017 Planned primary completion date changed from 30 Mar 2023 to 29 Dec 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com